Immune system protein may defend against deadly intestinal disease in babies – Washington University School of Medicine in St. Louis

Immune system protein may defend against deadly intestinal disease in babies – Washington University School of Medicine in St. Louis

  • June 16, 2021

Visit the News Hub

Findings may lead to new therapies for necrotizing enterocolitis

Getty Images

The intestinal disease necrotizing enterocolitis is a leading cause of death among premature infants born in the U.S. and across the globe. Characterized by excessive inflammation that can cause tissue decay in the bowels, the disease provides a pathway for infectious and deadly bacteria to enter the bloodstream.

Despite four decades of research, effective treatments remain elusive, and mortality rates in babies who develop the disease have remained essentially unchanged, hovering at about 30%.

Now, a study led by researchers at Washington University School of Medicine in St. Louis has identified, in mice, a protein in the immune system that may protect babies from necrotizing enterocolitis (NEC) and lead to the development of new treatments.

The findings are published online June 15 in Cell Reports Medicine.

“Necrotizing enterocolitis is a serious, fast-acting condition that can lead to death within hours,” said the study’s senior author, Misty Good, MD, an assistant professor of pediatrics in the Division of Newborn Medicine. “We don’t know why NEC happens, and we can try to treat it with antibiotics and surgical removal of the dead tissue; however, in severe cases, many babies will still die. No treatments stop the disease from progressing, but our hope is that the protein we’ve identified will change that.”

The scientists focused on Interleukin-22 (IL-22), a protein that regulates immune responses and helps maintain a healthy gut microbiome in adults.

Over the years, research has suggested that IL-22 has a critical role in adult gastrointestinal diseases. Consequently, potential treatments involving IL-22 are being studied in COVID-19 illness, alcohol-induced liver disease, and graft-versus-host disease that develops after organ or bone marrow transplants. However, IL-22’s role in newborns’ intestines has been unclear.

To better understand the protein’s role, the researchers created a mouse model to examine IL-22 signaling and production in healthy intestines and in intestines damaged by NEC. They analyzed IL-22 levels before and after birth and into adulthood, which for mice begins when they are weaned, at about 28 days old. In both the healthy and diseased intestines, the researchers documented low postnatal IL-22 production up until day 21, when production skyrocketed for the mice and continued into adulthood.

The researchers also studied tissue samples from preemies who did and did not develop NEC. The scientists found low levels of IL-22 in all of the intestinal samples. And in the babies who had developed NEC, an appropriate immune response had not been mounted in the intestines.

“Immune cells in the neonatal intestine have shown an inability to produce adequate amounts of IL-22 to control the progression of NEC,” said Good, who treats patients at St. Louis Children’s Hospital and is also co-program director of the university’s Neonatal-Perinatal Medicine Fellowship. As a member of the scientific advisory council of the Necrotizing Enterocolitis Society, Good has led an effort involving seven medical centers that have developed a large biorepository of samples from infants affected by NEC.

Good surmised that immature intestines are associated with a lack of IL-22 production, a theory strengthened by the fact that premature infants weighing less than 3 pounds 5 ounces are most at risk for NEC. Typically, the more premature a baby is, the lower the baby’s weight and the more undeveloped a baby’s gastrointestinal immune system is. Harmful bacteria can get cross the gut barrier and activate the immune system. And because the immune system of preemies isn’t fully developed, it leads to an exaggerated inflammatory response that can lead to tissue death.

The researchers’ findings of low levels of IL-22 in neonatal tissues led to their next step: injecting the mice with IL-22. The protein aids in controlling inflammation while promoting regeneration of tightly packed cells lining the intestine. IL-22 can help strengthen the intestinal walls, creating a barrier in the gut that allows for nutrient absorption while preventing toxic or otherwise hostile microorganisms from seeping into the bloodstream.

“Interestingly, our work demonstrated that treatment with IL-22, in mice, protects the newborn intestine against damage caused by NEC,” Good said. “Our study represents a substantial advance in understanding the role of IL-22 in early life and sets the stage for new ways to treat NEC in the future.”

Matt Miller

Misty Good, MD, an assistant professor of pediatrics in the Division of Newborn Medicine at Washington University School of Medicine in St. Louis, led research involving a protein in the immune system that may protect babies from necrotizing enterocolitis (NEC).

Mihi B, Gong Q, Nolan LS, Gale SE, Goree M, Hu E, Lanik WE, Rimer JM, LiuV, Parks OB, Lewis AN, Agrawal P, Laury ML, Kumar P, Huang E, Bidani SS, Luke CJ, Kolls JK, Good M. Interleukin-22 signaling attenuates necrotizing enterocolitis by promoting epithelial cell regeneration. Cell Reports Medicine. June 15, 2021. DOI: 10.1016/j.xcrm.2021.100320.

This research was funded by National Institutes of Health (NIH) grants R01DK118568, R03DK111473, K08DK101608, and 5T32HD043010; the March of Dimes Foundation, grant 5-FY17-79; the American Academy of Pediatrics Marshall Klaus Award, the St. Louis Children’s Hospital Foundation, the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital, and the Department of Pediatrics at Washington University School of Medicine.

Declaration of interests: Misty Good and Jay Kolls have a patent pending on the use of interleukin-22 to prevent or treat necrotizing enterocolitis. Good has received sponsored research agreement funding from Astarte Medical, Evive Biotech and Takeda Pharmaceuticals. Good serves on the Scientific Advisory Council of the NEC Society, and the Clinical and Technology Advisory Board of Astarte Medical. She participated in a neonatal microbiome advisory board for Abbott Laboratories in 2019. None of these sources had any role in this study.

Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.


admincis

E-mail : cis@capsimmunesystem.org

capsimmunesystem.org